HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Abbott, K. Articles by Bakris, G. L. Search for Related Content PubMed PubMed Citation Articles by Abbott, K. Articles by Bakris, G. L. Social Bookmarking                         What's this?

Blood Pressure Control and Nephroprotection in Diabetes

Walter Reed Army Hospital, Department of Medicine, Division of Nephrology, Bethesda, Maryland (K. Abbott) and Rush Presbyterian/St. Luke's Medical Center, Department of Medicine, Hypertension/Clinical Research Center, Chicago (E. Basta, G. L. Bakris).

Achievement of recommended levels of blood pressure as prescribed by guidelines (i.e., systolic blood pressure of < 130 mmHg in people with nephropathy secondary to type 2 diabetes) generally requires three or more different antihypertensive agents that have complementary modes of action. This systolic goal blood pressure, recommended by generally all international guideline committees, was derived from largely observational studies demonstrating a greater reduction of cardiovascular risk and preservation of kidney function at these levels. Commonly used antihypertensive combinations include angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers, which have compelling indications for use in people with kidney disease and/or diabetes, combined with a diuretic, generally a thiazide-type agent. If additional therapy is required, either a beta-blocker or a calcium antagonist may be added to this antihypertensive "cocktail." Beta-blockers are particularly effective in people with a high sympathetic drive (i.e., high pulse rates) to lower blood pressure and reduce cardiovascular risk. Moreover, in recent studies, their benefits on kidney function, both by reducing macroalbuminuria and slowing the decline of kidney function, make them good agents to add in the appropriate clinical setting. With all these potential benefits of achieving blood pressure goals, it is unfortunate that only 11% of people being treated for hypertension with diabetic kidney disease achieve the blood pressure goal of < 130 mmHg, likely contributing to the climbing incidence of people starting dialysis. Physicians need to work harder and educate patients on the importance of achieving these lower blood pressure guidelines.

Key Words: Diabetes • nephropathy • hypertension • ACE inhibitors • angiotensin • receptor

Address for reprints: George L. Bakris, MD, Rush Presbyterian/St. Luke's Medical Center, 1700 W. Van Buren Street, Suite 470, Chicago, IL 60612.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Zheng, E. C. Carlson, L. Yang, P. M. Kralik, Y. Huang, and P. N. Epstein Podocyte-Specific Overexpression of the Antioxidant Metallothionein Reduces Diabetic Nephropathy J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2077 - 2085. [Abstract] [Full Text] [PDF]

				L. M. Prisant Diabetes Mellitus: An Imperative for Prevention and Intense Management J. Clin. Pharmacol., April 1, 2004; 44(4): 394 - 396. [Full Text] [PDF]